RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm
RCEL(NASDAQ:RCEL) LOS ANGELES--(BUSINESS WIRE)---- $RCEL--RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm
RCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about Investigation
RCEL(NASDAQ:RCEL) NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ:RCEL) investors concerning the Company’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 7, 2025, AVITA released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell proced
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
RCELLOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVITA MEDICAL, INC. (RCEL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August
AVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
RCELBENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AVITA MEDICAL, INC. (RCEL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by ema
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
RCELLOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVITA MEDICAL, INC. (RCEL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 7, 2025, Avita released its second quarter 2025 financial
D. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target
RCELAVITA Medical Highlights Data Presented By Researchers At BBA Annual Meeting Demonstrating Reduced Length Of Hospital Stay Among Burn Patients Treated With RECELL
RCELD. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target
RCELAVITA Medical Says First Clinical Publication Evaluating Cohealyx, AVITA Medical-Branded Collagen-Based Dermal Matrix, Published In Journal Of Surgery
RCELAVITA Medical Affirms FY2025 Commercial Revenue Guidance of $100.00M-$106.00M vs $102.26M Est
RCELAVITA Medical Q1 EPS $(0.53) Misses $(0.39) Estimate, Sales $18.51M Miss $21.14M Estimate
RCELD. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target
RCEL6 Analysts Assess AVITA Medical: What You Need To Know
RCELD. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target
RCELWhat Analysts Are Saying About AVITA Medical Stock
RCELD. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target
RCELAVITA Medical Enters New Contract Manufacturing Agreement For PermeaDerm Biosynthetic Wound Matrix, Along With Amendment To Existing Exclusive Distribution Deal With Stedical Scientific
RCELD. Boral Capital Maintains Buy on AVITA Medical, Lowers Price Target to $22
RCELAnalyst Expectations For AVITA Medical's Future
RCELD. Boral Capital Maintains Buy on AVITA Medical, Maintains $25 Price Target
RCELAVITA Medical Affirms FY2025 Sales Guidance of $100.00M-$106.00M vs $103.83M Est
RCELAVITA Medical Q4 EPS $(0.44) Misses $(0.43) Estimate, Sales $18.41M Miss $21.04M Estimate
RCELCantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $21 Price Target
RCELD. Boral Capital Initiates Coverage On AVITA Medical with Buy Rating, Announces Price Target of $25
RCELAvita Medical Announced The FDA Has Approved Its Premarket Approval Supplement For RECELL GO Mini Disposable Cartridge Designed Specifically To Treat Smaller Wounds
RCELAVITA Medical Secures FDA 510(k) Clearance For Cohealyx
RCELAVITA Shares Climb Following Positive Results From RECELL System Study In Stable Vitiligo Lesions
RCELAVITA Medical (NASDAQ: RCEL) reveals positive top-line results from a pivotal trial evaluating the safety and effectiveness of the RECELL System for repigmentation of stable vitiligo lesions.
AVITA Medical Reports Topline Pivotal Trial Results For Treatment Of Stable Vitiligo Using The RECELL® System; Co. Reports 'The study achieved its primary effectiveness endpoint of super-superiority'
RCEL